Gilead Sciences Current Ratio 2010-2022 | GILD
Current and historical current ratio for Gilead Sciences (GILD) from 2010 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Gilead Sciences current ratio for the three months ending September 30, 2022 was 1.30.
| Gilead Sciences Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2022-09-30 |
$13.55B |
$10.42B |
1.30 |
| 2022-06-30 |
$13.18B |
$9.22B |
1.43 |
| 2022-03-31 |
$12.63B |
$8.56B |
1.48 |
| 2021-12-31 |
$14.77B |
$11.61B |
1.27 |
| 2021-09-30 |
$13.99B |
$10.25B |
1.37 |
| 2021-06-30 |
$13.93B |
$10.21B |
1.36 |
| 2021-03-31 |
$13.28B |
$9.71B |
1.37 |
| 2020-12-31 |
$16.00B |
$11.40B |
1.40 |
| 2020-09-30 |
$30.93B |
$9.51B |
3.25 |
| 2020-06-30 |
$24.64B |
$10.56B |
2.33 |
| 2020-03-31 |
$26.95B |
$8.88B |
3.04 |
| 2019-12-31 |
$30.30B |
$9.76B |
3.10 |
| 2019-09-30 |
$28.36B |
$9.57B |
2.96 |
| 2019-06-30 |
$33.73B |
$8.96B |
3.76 |
| 2019-03-31 |
$34.02B |
$9.40B |
3.62 |
| 2018-12-31 |
$35.84B |
$10.61B |
3.38 |
| 2018-09-30 |
$34.92B |
$10.12B |
3.45 |
| 2018-06-30 |
$32.73B |
$10.91B |
3.00 |
| 2018-03-31 |
$30.26B |
$10.67B |
2.84 |
| 2017-12-31 |
$31.82B |
$11.64B |
2.74 |
| 2017-09-30 |
$35.32B |
$9.60B |
3.68 |
| 2017-06-30 |
$28.59B |
$8.49B |
3.37 |
| 2017-03-31 |
$21.42B |
$8.28B |
2.59 |
| 2016-12-31 |
$19.59B |
$9.22B |
2.13 |
| 2016-09-30 |
$21.43B |
$11.07B |
1.94 |
| 2016-06-30 |
$18.35B |
$10.44B |
1.76 |
| 2016-03-31 |
$19.27B |
$10.91B |
1.77 |
| 2015-12-31 |
$24.76B |
$9.89B |
2.50 |
| 2015-09-30 |
$25.91B |
$9.36B |
2.77 |
| 2015-06-30 |
$18.09B |
$8.93B |
2.03 |
| 2015-03-31 |
$20.06B |
$7.43B |
2.70 |
| 2014-12-31 |
$17.71B |
$5.76B |
3.08 |
| 2014-09-30 |
$12.56B |
$6.06B |
2.08 |
| 2014-06-30 |
$15.50B |
$6.23B |
2.49 |
| 2014-03-31 |
$12.97B |
$5.92B |
2.19 |
| 2013-12-31 |
$7.00B |
$6.41B |
1.09 |
| 2013-09-30 |
$6.97B |
$4.90B |
1.42 |
| 2013-06-30 |
$7.07B |
$4.94B |
1.43 |
| 2013-03-31 |
$6.66B |
$4.29B |
1.55 |
| 2012-12-31 |
$6.16B |
$4.24B |
1.45 |
| 2012-09-30 |
$5.88B |
$4.80B |
1.23 |
| 2012-06-30 |
$5.84B |
$4.99B |
1.17 |
| 2012-03-31 |
$5.83B |
$4.19B |
1.39 |
| 2011-12-31 |
$13.92B |
$2.52B |
5.54 |
| 2011-09-30 |
$6.15B |
$2.22B |
2.76 |
| 2011-06-30 |
$6.22B |
$2.31B |
2.69 |
| 2011-03-31 |
$6.85B |
$2.77B |
2.47 |
| 2010-12-31 |
$5.71B |
$2.47B |
2.32 |
| 2010-09-30 |
$6.03B |
$2.59B |
2.33 |
| 2010-06-30 |
$5.71B |
$3.11B |
1.84 |
| 2010-03-31 |
$5.12B |
$1.89B |
2.72 |
| 2009-12-31 |
$4.81B |
$1.87B |
2.57 |
| 2009-09-30 |
$4.30B |
$1.89B |
2.28 |
| 2009-06-30 |
$4.00B |
$1.78B |
2.25 |
| 2009-03-31 |
$4.62B |
$1.26B |
3.66 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$104.541B |
$27.305B |
|
Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.
|
